Literature DB >> 1499163

Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts.

K Morozumi1, G Thiel, F W Albert, G Banfi, F Gudat, M J Mihatsch.   

Abstract

Cyclosporine (CSA)-associated arteriolopathy (CAA) is the second most frequent morphological diagnosis in renal allografts and its final outcome remains unclear. The present study was performed to clarify the morphological outcome of CAA by follow-up histological analysis after stopping CSA. Furthermore, the clinical management of patients showing CAA is discussed. Most of the patients came from our early experience with CSA between 1981-1983 when CSA doses and trough levels were high. Twenty recipients were divided into two groups according to the presence of CAA after stopping CSA: group A (n = 9) showed persistent CAA and group B (n = 11) showed no CAA. The majority of the patients, including five incomplete remission in group A, showed obvious improvement of CAA even if the arterioles were severely affected. Improvement of CAA was noted a few months after stopping CSA or after lower dose CSA therapy. There were no significant differences in CSA blood levels or duration of CSA therapy between the groups. The severity of preexistent CAA was significantly greater in group A. Only two patients who died from malignant tumor showed exacerbation of CAA. Eight patients died and eight grafts were lost, seven due to vascular rejection and one to hemolytic uremic syndrome-like CAA. Poor renal function was also noted in four cases with functioning graft owing to vascular rejection even though the improvement of CAA was evident. The complete regression of CAA and the remodelling of arterioles showing well preserved vascular patency were frequently found after stopping or reducing the dose of CSA.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1499163

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

2.  Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.

Authors:  Martin-Walter Welker; Nina Weiler; Wolf Otto Bechstein; Eva Herrmann; Christoph Betz; Mark Schöffauer; Stefan Zeuzem; Christoph Sarrazin; Kerstin Amann; Oliver Jung
Journal:  J Nephrol       Date:  2018-06-26       Impact factor: 3.902

3.  Vasa recta hyalinosis reflects severe arteriolopathy in renal allografts.

Authors:  Hideyo Oguchi; Ken Sakai; Yutaka Yamaguchi; Tetuo Mikami; Tetsuo Nemoto; Yasushi Ohashi; Takeshi Kawamura; Masaki Muramatsu; Yoshihiro Itabashi; Kazunobu Shinoda; Yoji Hyodo; Yusuke Takahashi; Yuki Kawaguchi; Hiroka Onishi; Yuko Hamasaki; Kazutoshi Shibuya; Seiichiro Shishido
Journal:  Clin Exp Nephrol       Date:  2019-02-08       Impact factor: 2.801

Review 4.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

5.  Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results.

Authors:  Kota Takahashi; Kazuharu Uchida; Norio Yoshimura; Shiro Takahara; Satoshi Teraoka; Rie Teshima; Catherine Cornu-Artis; Eiji Kobayashi
Journal:  Transplant Res       Date:  2013-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.